Biogen logo is seen at its headquarters in Cambridge, Massachusetts. Credit: Tada Images/Adobe Stock 'Unfair Business Practices'?: Lawsuits Allege Big Pharma Multiple Sclerosis Drug Monopoly
"Biogen's anticompetitive conduct, and the PBMs' participation in it, delayed and substantially diminished the sale of generic Tecfidera in the United States, and unlawfully enabled Biogen to sell Tecfidera and Vumerity at artificially inflated units and prices," according to the allegations in three complaints accusing Biogen of monopolizing the multiple sclerosis drug market.
September 26, 2024 at 07:07 PM
3 minute read
Antitrust
The original version of this story was published on National Law Journal
What You Need to Know
- Three lawsuits allege Biogen Inc. forces multiple sclerosis patients to overpay for their medication.
- Baltimore city officials and other plaintiffs accuse Biogen of monopolizing the MS drug market.
- Biogen received FDA approval of Tecfidera in 2013 and Vumerity in 2019 for treating MS.
A global drug company that makes life-saving treatments for multiple sclerosis is accused of impairing generic competition and forcing sufferers of MS to overpay for their medication.
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Law Firms Mentioned
Trending Stories
- 1The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 2Wine, Dine and Grind (Through the Weekend): Summer Associates Thirst For Experience in 'Real Matters'
- 3The 'Biden Effect' on Senior Attorneys: Should I Stay or Should I Go?
- 4'That's Disappointing': Only 11% of MDL Appointments Went to Attorneys of Color in 2023
- 5'You Are Not Alone': 120 Sex Assault Victims Plan to Sue Sean 'Diddy' Combs
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
